EHA 2020: New anti-cancer peptide-drug conjugate Melflufen treatment of refractive multiple myeloma, Phase 2 HORIZON trial successful

At the 25th Meeting of the European Hematology Association, Oncopeptides announced the main results of the Phase 2 HORIZON study on the treatment of patients with recurrent refractive merilloma (RRMM) in patients with intravenous Melflufen joint desemimasonThe results will support an NDA application to the U.SFood and DrugAdministration(FDA) to expedite Melflufen's approvalThe main results of theare as follows:Melflufen is a new anti-cancer peptide-drug conjugate, a new peptide hinge alkanel acting on intracellular amino peptide enzymes, which is highly expressed in multiple myelomaHORIZON studies have shown that Melflufen, which is associated with dexamethasone, may provide new treatment options for patients with RRMM who are difficult to treat and have poor prognosis, including tertiary refractive myelomaThe patient's long-lasting response and deepenover over time indicate that the patient can benefit from treatment for as long as possibleThe results are consistent with the previously reported data, but no new security risks have been identified"Horizon data is an important milestone for Oncopeptides and further validates our peptide-drug coupling platform," said M.D., oncopeptidesThe results are consistent with previous interim analysis resultsIt is important to note that the PFS in patients with reaction (all previously treated and third-degree refractive patients) was 8.5 months, significantly higher than DOR, which is very encouraging for patients whose needs are not met"